摘要
为了评价新喹诺酮类药物左氧氟沙星、司帕沙星治疗伤寒的临床疗效,以国产和进口左氧氟沙星片剂、司帕沙星和氧氟沙星片剂分别做随机对照试验治疗急性伤寒共70例。左氧氟沙星200mg口服,每日2次,疗程7天;司帕沙星300mg口服,每日1次,疗程7～10天;氧氟沙星300mg口服,每日2次,疗程7～10天。
The aim of the study was to study therapeutic
efficacy and side reactions of new fluoroquinolone,
levofloxacin (LVFX) and sparfloxacin (SPFX), in
the treatment of typhoid fever. 70 patients with
acute typhoid fever were randomly distributed into
domestic LVFX group (n = 15), imported LVFX
group (n = 15), SPFX group (n = 21) and OFX
group (n = 19). LVFX 200mg twice daily for 7
days, SPFX 300mg once daily for 7 to 10 days,
and OFX 300mg twice daily for 7 to 10 days was
respectively given to the patients. At month 1 and
3 after stopping treatment, the stools of the
patients were cultured for typhoid bacteria to
evaluate the clinical efficacy of the drugs. The
results showed that both clinical cure rate and clear
rate of the bacteria were 100% in all groups, and
the efficacy of domestic LVFX was not different
from the imported drug. (P>0. 05). The
defervescent days of the patients treated with
SPFX were shorter than with OFX (P<0. 01).
There was no case of clinical relapse in the treated
patients at month 1 and 3 after stopping the drugs,
and there was no any severe adversity caused by all
of the drugs. The MIC_(90) of LVFX, SPFX and OFX
was 0. 125mg/L, 0. 06mg/L and 0. 25mg/L,
respectively. The results indicate that LVFX or
SPFX can be selected to treat typhoid fever
because of its efficacy and safety, and domestic
LVFX has same therapeutic effects as the imported
one.
出处
《传染病信息》
1998年第4期168-169,共2页
Infectious Disease Information
